Frequent cases of RAS-mutated down syndrome acute lymphoblastic leukaemia lack JAK2 mutations

• المؤلفون الرئيسيون: Nikolaev, Sergey I., Garieri, Marco, Santoni, Federico, Falconnet, Emilie, Ribaux, Pascale, Guipponi, Michel, Murray, Aoife, Groet, Jürgen, Giarin, Emanuela, Basso, Giuseppe, Nizetic, Dean, Antonarakis, Stylianos E.
• مؤلفون آخرون: Lee Kong Chian School of Medicine (LKCMedicine)
• التنسيق: مقال
• اللغة: English
• منشور في: 2014
• الموضوعات: DRNTU::Science::Biological sciences::Human anatomy and physiology
• الوصول للمادة أونلاين: https://hdl.handle.net/10356/101511; http://hdl.handle.net/10220/24153

Children with Down syndrome (DS) and acute lymphoblastic leukaemia (ALL) have poorer survival and more relapses than non-DS children with ALL, highlighting an urgent need for deeper mechanistic understanding of DS–ALL. Here, using full-exome or cancer genes-targeted sequencing of 42 ALL samples from 39 DS patients, we uncover driver mutations in RAS, (​KRAS and ​NRAS) recurring to a similar extent (15/42) as ​JAK2 (12/42) mutations or ​P2RY8-​CRLF2 fusions (14/42). RAS mutations are almost completely mutually exclusive with ​JAK2 mutations (P=0.016), driving a combined total of two-thirds of analysed cases. Clonal architecture analysis reveals that both RAS and ​JAK2 drove sub-clonal expansions primarily initiated by ​CRLF2 rearrangements, and/or mutations in chromatin remodellers and lymphocyte differentiation factors. Remarkably, in 2/3 relapsed cases, there is a switch from a primary ​JAK2- or ​PTPN11-mutated sub-clone to a RAS-mutated sub-clone in relapse. These results provide important new insights informing the patient stratification strategies for targeted therapeutic approaches for DS–ALL.